SciClone Pharmaceuticals Inc. (SCLN) Stake Lowered by First Trust Advisors LP
First Trust Advisors LP reduced its position in SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) by 5.1% during the second quarter, Holdings Channel reports. The fund owned 25,759 shares of the specialty pharmaceutical company’s stock after selling 1,384 shares during the period. First Trust Advisors LP owned approximately 0.05% of SciClone Pharmaceuticals worth $336,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of SCLN. Acrospire Investment Management LLC purchased a new position in shares of SciClone Pharmaceuticals during the first quarter valued at about $103,000. Suntrust Banks Inc. raised its position in shares of SciClone Pharmaceuticals by 3.8% in the second quarter. Suntrust Banks Inc. now owns 11,938 shares of the specialty pharmaceutical company’s stock valued at $155,000 after buying an additional 432 shares in the last quarter. Fox Run Management L.L.C. purchased a new position in shares of SciClone Pharmaceuticals during the second quarter valued at about $180,000. Capstone Asset Management Co. purchased a new position in shares of SciClone Pharmaceuticals during the second quarter valued at about $197,000. Finally, BNP Paribas Arbitrage SA purchased a new position in shares of SciClone Pharmaceuticals during the second quarter valued at about $204,000. Institutional investors and hedge funds own 79.60% of the company’s stock.
Shares of SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) traded down 0.10% during trading on Friday, reaching $10.01. The company had a trading volume of 177,123 shares. The firm has a 50 day moving average price of $10.29 and a 200 day moving average price of $11.83. The company has a market cap of $499.89 million, a price-to-earnings ratio of 13.51 and a beta of 1.47. SciClone Pharmaceuticals Inc. has a 12 month low of $7.13 and a 12 month high of $15.02.
SciClone Pharmaceuticals (NASDAQ:SCLN) last posted its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $0.20 EPS for the quarter. SciClone Pharmaceuticals had a net margin of 24.02% and a return on equity of 24.43%. The company earned $39 million during the quarter, compared to the consensus estimate of $37.90 million. Analysts predict that SciClone Pharmaceuticals Inc. will post $0.33 earnings per share for the current year.
In other news, CEO Friedhelm Blobel sold 501,875 shares of the stock in a transaction dated Wednesday, August 17th. The shares were sold at an average price of $10.00, for a total transaction of $5,018,750.00. Following the completion of the transaction, the chief executive officer now directly owns 588,255 shares in the company, valued at approximately $5,882,550. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Nancy T. Chang sold 25,040 shares of the stock in a transaction dated Tuesday, August 30th. The stock was sold at an average price of $10.30, for a total transaction of $257,912.00. Following the transaction, the director now owns 29,019 shares of the company’s stock, valued at $298,895.70. The disclosure for this sale can be found here. Insiders own 7.63% of the company’s stock.
SciClone Pharmaceuticals Company Profile
SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.
Want to see what other hedge funds are holding SCLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SciClone Pharmaceuticals Inc. (NASDAQ:SCLN).
Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.